Metabolic syndrome and cardiovascular risk

被引:63
作者
Alshehri, Abdullah M. [1 ]
机构
[1] King Fahd Hosp Univ, Dept Internal Med, POB 40294, Al Khobar 31952, Saudi Arabia
关键词
Metabolic syndrome; risk; cardiovascular;
D O I
10.4103/1319-1683.71987
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The constellation of dyslipidemia (hypertriglyceridemia and low levels of high-density lipoprotein cholesterol), elevated blood pressure, impaired glucose tolerance, and central obesity is now classified as metabolic syndrome, also called syndrome X. In the past few years, several expert groups have attempted to set forth simple diagnostic criteria for use in clinical practice to identify patients who manifest the multiple components of the metabolic syndrome. These criteria have varied somewhat in specific elements, but in general, they include a combination of multiple and metabolic risk factors. The most widely recognized of the metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics, commonly manifest a prothrombotic state as well as and a proinflammatory state. Atherogenic dyslipidemia consists of an aggregation of lipoprotein abnormalities including elevated serum triglyceride and apolipoprotein B (apoB), increased small LDL particles, and a reduced level of HDL cholesterol (HDL-C). The metabolic syndrome is oft en referred to as if it were a discrete entity with a single cause. Available data suggest that it truly is a syndrome, ie, a grouping of atherosclerotic cardiovascular disease (ASCVD) risk factors, that probably has more than one cause. Regardless of cause, the syndrome identifies individuals at an elevated risk for ASCVD. The magnitude of the increased risk can vary according to the components of the syndrome present as well as the other, non-metabolic syndrome risk factors in a particular person.
引用
收藏
页码:73 / 78
页数:6
相关论文
共 44 条
[1]   RELATIONSHIPS OF GENERALIZED AND REGIONAL ADIPOSITY TO INSULIN SENSITIVITY IN MEN [J].
ABATE, N ;
GARG, A ;
PESHOCK, RM ;
STRAYGUNDERSEN, J ;
GRUNDY, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :88-98
[2]  
Al-Nozha MM, 2005, SAUDI MED J, V26, P1918
[3]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[4]  
2-S
[5]   Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome [J].
Apridonidze, T ;
Essah, PA ;
Iuorno, MJ ;
Nestler, JE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (04) :1929-1935
[6]  
Balkau B, 1999, DIABETIC MED, V16, P442
[7]   Central role of the adipocyte in the metabolic syndrome [J].
Bergman, RN ;
Van Citters, GW ;
Mittelman, SD ;
Dea, MK ;
Hamilton-Wessler, M ;
Kim, SP ;
Ellmerer, M .
JOURNAL OF INVESTIGATIVE MEDICINE, 2001, 49 (01) :119-126
[8]   Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women [J].
Brochu, M ;
Starling, RD ;
Tchernof, A ;
Matthews, DE ;
Garcia-Rubi, E ;
Poehlman, ET .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (07) :2378-2384
[9]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[10]   Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men [J].
Chandalia, M ;
Abate, N ;
Garg, A ;
Stray-Gundersen, J ;
Grundy, SM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (07) :2329-2335